These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 24363530)
21. Risk factors for hepatocellular carcinoma in patients with drug-resistant chronic hepatitis B. Jun CH; Hong HJ; Chung MW; Park SY; Cho SB; Park CH; Joo YE; Kim HS; Choi SK; Rew JS World J Gastroenterol; 2013 Oct; 19(40):6834-41. PubMed ID: 24187458 [TBL] [Abstract][Full Text] [Related]
22. Long-term follow-up of cumulative incidence of hepatocellular carcinoma in hepatitis B virus patients without antiviral therapy. Jiang XY; Huang B; Huang DP; Wei CS; Zhong WC; Peng DT; Huang FR; Tong GD World J Gastroenterol; 2021 Mar; 27(11):1101-1116. PubMed ID: 33776376 [TBL] [Abstract][Full Text] [Related]
23. De novo combined lamivudine and adefovir dipivoxil therapy vs entecavir monotherapy for hepatitis B virus-related decompensated cirrhosis. Lian JS; Zeng LY; Chen JY; Jia HY; Zhang YM; Xiang DR; Yu L; Hu JH; Lu YF; Zheng L; Li LJ; Yang YD World J Gastroenterol; 2013 Oct; 19(37):6278-83. PubMed ID: 24115827 [TBL] [Abstract][Full Text] [Related]
24. Relationship between hepatocellular carcinoma and hepatitis B virus genotype with spontaneous YMDD mutations. Yang JH; Zhang H; Chen XB; Chen G; Wang X World J Gastroenterol; 2013 Jun; 19(24):3861-5. PubMed ID: 23840126 [TBL] [Abstract][Full Text] [Related]
25. Nucleos(t)ide Analogue Treatment for Patients With Hepatitis B Virus (HBV) e Antigen-Positive Chronic HBV Genotype C Infection: A Nationwide, Multicenter, Retrospective Study. Chang Y; Choe WH; Sinn DH; Lee JH; Ahn SH; Lee H; Shim JJ; Jun DW; Park SY; Nam JY; Cho EJ; Yu SJ; Lee DH; Lee JM; Kim YJ; Kwon SY; Paik SW; Yoon JH J Infect Dis; 2017 Dec; 216(11):1407-1414. PubMed ID: 29029102 [TBL] [Abstract][Full Text] [Related]
26. Efficacy of lamivudine therapy for decompensated liver cirrhosis due to hepatitis B virus with or without hepatocellular carcinoma. Hiraoka A; Michitaka K; Kumagi T; Kurose K; Uehara T; Hirooka M; Yamashita Y; Kubo Y; Miyaoka H; Iuchi H; Okada S; Ohmoto M; Yamamoto K; Horiike N; Onji M Oncol Rep; 2005 Jun; 13(6):1159-63. PubMed ID: 15870937 [TBL] [Abstract][Full Text] [Related]
27. Management of chronic hepatitis B in severe liver disease. Fung J; Lai CL; Yuen MF World J Gastroenterol; 2014 Nov; 20(43):16053-61. PubMed ID: 25473157 [TBL] [Abstract][Full Text] [Related]
28. Stratification of hepatocellular carcinoma risk through modified FIB-4 index in chronic hepatitis B patients on entecavir therapy. Wang HW; Lai HC; Hu TH; Su WP; Lu SN; Lin CH; Hung CH; Chuang PH; Wang JH; Lee MH; Chen CH; Peng CY J Gastroenterol Hepatol; 2019 Feb; 34(2):442-449. PubMed ID: 29968933 [TBL] [Abstract][Full Text] [Related]
29. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. Su TH; Hu TH; Chen CY; Huang YH; Chuang WL; Lin CC; Wang CC; Su WW; Chen MY; Peng CY; Chien RN; Huang YW; Wang HY; Lin CL; Yang SS; Chen TM; Mo LR; Hsu SJ; Tseng KC; Hsieh TY; Suk FM; Hu CT; Bair MJ; Liang CC; Lei YC; Tseng TC; Chen CL; Kao JH; Liver Int; 2016 Dec; 36(12):1755-1764. PubMed ID: 27634134 [TBL] [Abstract][Full Text] [Related]
30. Prevention of hepatocellular carcinoma in hepatitis B virus infection. Lim SG; Mohammed R; Yuen MF; Kao JH J Gastroenterol Hepatol; 2009 Aug; 24(8):1352-7. PubMed ID: 19702903 [TBL] [Abstract][Full Text] [Related]
31. Long-term lamivudine for chronic hepatitis B and cirrhosis: A real-life cohort study. Su MH; Lu AL; Li SH; Zhong SH; Wang BJ; Wu XL; Mo YY; Liang P; Liu ZH; Xie R; He LX; Fu WD; Jiang JN World J Gastroenterol; 2015 Dec; 21(46):13087-94. PubMed ID: 26673249 [TBL] [Abstract][Full Text] [Related]
32. Management of hepatitis B virus infection during treatment for hepatitis B virus-related hepatocellular carcinoma. Kubo S; Takemura S; Tanaka S; Shinkawa H; Nishioka T; Nozawa A; Kinoshita M; Hamano G; Ito T; Urata Y World J Gastroenterol; 2015 Jul; 21(27):8249-55. PubMed ID: 26217076 [TBL] [Abstract][Full Text] [Related]
33. Revised Korean Antiviral Guideline Reduces the Hepatitis B-related Hepatocellular Carcinoma Risk in Cirrhotic Patients. Kim DS; Park SY; Kim BK; Park JY; Kim DY; Han KH; Lee YR; Tak WY; Kweon YO; Jung I; Han M; Kim EH; Ahn SH; Kim SU J Korean Med Sci; 2021 Apr; 36(16):e105. PubMed ID: 33904261 [TBL] [Abstract][Full Text] [Related]
34. Nucleos(t)ide analogues causes HBV S gene mutations and carcinogenesis. Wang ML; Tang H Hepatobiliary Pancreat Dis Int; 2016 Dec; 15(6):579-586. PubMed ID: 27919846 [TBL] [Abstract][Full Text] [Related]
35. Prophylaxis against hepatitis B virus recurrence after liver transplantation: a registry study. Shen S; Jiang L; Xiao GQ; Yan LN; Yang JY; Wen TF; Li B; Wang WT; Xu MQ; Wei YG World J Gastroenterol; 2015 Jan; 21(2):584-92. PubMed ID: 25593480 [TBL] [Abstract][Full Text] [Related]
36. Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease. Cho JY; Paik YH; Sohn W; Cho HC; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC Gut; 2014 Dec; 63(12):1943-50. PubMed ID: 24615378 [TBL] [Abstract][Full Text] [Related]
37. Fibrosis-matched outcomes between chronic hepatitis B patients with drug-induced virological response and inactive carriers. Kim HS; Baatarkhuu O; Lee HW; Park JY; Kim DY; Ahn SH; Song K; Han KH; Kim BK; Kim SU Liver Int; 2019 Jan; 39(1):81-89. PubMed ID: 30280461 [TBL] [Abstract][Full Text] [Related]
38. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. Papatheodoridis GV; Lampertico P; Manolakopoulos S; Lok A J Hepatol; 2010 Aug; 53(2):348-56. PubMed ID: 20483498 [TBL] [Abstract][Full Text] [Related]
39. Prognosis of Untreated Minimally Active Chronic Hepatitis B Patients in Comparison With Virological Responders by Antivirals. Lee HW; Kim SU; Park JY; Baatarkhuu O; Kim DY; Ahn SH; Han KH; Kim BK Clin Transl Gastroenterol; 2019 Jun; 10(6):e00036. PubMed ID: 31107725 [TBL] [Abstract][Full Text] [Related]
40. Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis. Mettke F; Schlevogt B; Deterding K; Wranke A; Smith A; Port K; Manns MP; Vogel A; Cornberg M; Wedemeyer H Aliment Pharmacol Ther; 2018 Feb; 47(4):516-525. PubMed ID: 29205405 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]